Enliven Therapeutics aligns with FDA on Phase 3 ENABLE-2 trial design for relcobatinib in previously treated CML
ELVN•Enliven Therapeutics reached FDA alignment on the Phase 3 ENABLE-2 trial design for relcobatinib in previously treated chronic myeloid leukemia and plans to start the study before year-end 2026.
1. Trial design aligned
The head-to-head pivotal trial will test whether relcobatinib can deliver better patient response than standard second-generation targeted therapies in previously treated chronic myeloid leukemia. Results have not been presented; positive outcomes could support a potential registrational path.
